Lenz Therapeutics Inc. and Lunatus Marketing & Consulting FZCO announced an exclusive distribution agreement for Lunatus to register and commercialize Vizz for the treatment of presbyopia in the Middle East Region. Lenz Therapeutics is a pharmaceutical company focused on the commercialization of Vizz (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Lunatus is an independent pharmaceutical company specializing in the commercialization of pharmaceutical products in the Middle East.

Under the terms of the agreement, Lenz will receive upfront, regulatory, and commercial milestone payments, in addition to a significant share of revenue generated in the region through a predetermined minimum product supply price. Lunatus will retain exclusive commercialization rights for Vizz for the treatment of presbyopia in the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq.